Caldaret

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 584691

CAS#: 133804-44-1

Description: Caldaret is an intracellular Ca2+ handling modulator that may have cardiotonic effects.


Chemical Structure

img
Caldaret
CAS# 133804-44-1

Theoretical Analysis

MedKoo Cat#: 584691
Name: Caldaret
CAS#: 133804-44-1
Chemical Formula: C11H16N2O3S
Exact Mass: 256.0882
Molecular Weight: 256.32
Elemental Analysis: C, 51.55; H, 6.29; N, 10.93; O, 18.73; S, 12.51

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Caldaret; MCC 135; MCC-135; MCC135

IUPAC/Chemical Name: Benzenesulfonic acid, 5-methyl-2-(1-piperazinyl)-

InChi Key: DCDFLGVJWQIRGH-UHFFFAOYSA-N

InChi Code: InChI=1S/C11H16N2O3S/c1-9-2-3-10(11(8-9)17(14,15)16)13-6-4-12-5-7-13/h2-3,8,12H,4-7H2,1H3,(H,14,15,16)

SMILES Code: O=S(C1=CC(C)=CC=C1N2CCNCC2)(O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

Preparing Stock Solutions

The following data is based on the product molecular weight 256.32 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Beranek JT. MCC-135 diminishes the egress of CK-MB but not of troponin-I from cardiomyocytes during reperfusion. Ann Thorac Surg. 2005 Mar;79(3):1095; author reply 1095. PubMed PMID: 15734461.

2: Kawasumi H, Satoh N, Kitada Y. Caldaret, an intracellular Ca2+ handling modulator, limits infarct size of reperfused canine heart. J Pharmacol Sci. 2007 Feb;103(2):222-33. Epub 2007 Feb 14. PubMed PMID: 17299242.

3: Jang IK, Pettigrew V, Picard MH, Kowey PR, Demmel V, Zile MR, Tatsuno J, Wackers FJ, Hibberd M. A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: rationale and design of the evaluation of MCC-135 for left ventricular salvage in acute MI (EVOLVE) study. J Thromb Thrombolysis. 2005 Dec;20(3):147-53. PubMed PMID: 16261287.

4: Satoh N, Kitada Y. Cardioprotective effect of MCC-135 is associated with inhibition of Ca2+ overload in ischemic/reperfused hearts. Eur J Pharmacol. 2004 Sep 19;499(1-2):179-87. PubMed PMID: 15363965.

5: Satoh N, Sato T, Shimada M, Yamada K, Kitada Y. Lusitropic effect of MCC-135 is associated with improvement of sarcoplasmic reticulum function in ventricular muscles of rats with diabetic cardiomyopathy. J Pharmacol Exp Ther. 2001 Sep;298(3):1161-6. PubMed PMID: 11504815.

6: Jang IK, Weissman NJ, Picard MH, Zile MR, Pettigrew V, Shen S, Tatsuno J, Hibberd MG, Tzivoni D, Wackers FJ; EVOLVE Investigators. A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: Evaluation of MCC-135 for left ventricular salvage in acute myocardial infarction (EVOLVE). Am Heart J. 2008 Jan;155(1):113.e1-8. Epub 2007 Nov 1. PubMed PMID: 18082500.

7: Tzivoni D, Balkin J, Bär FW, Hibberd M, Reiber JH, Cowing G. Effect of caldaret on the incidence of severe left ventricular dysfunction in patients with ST-elevation myocardial infarction undergoing primary coronary intervention. Am J Cardiol. 2009 Jan 1;103(1):1-4. doi: 10.1016/j.amjcard.2008.08.047. Epub 2008 Oct 23. PubMed PMID: 19101220.

8: Zile M, Gaasch W, Little W, Francis G, Tavazzi L, Cleland J, Davies M; MCC-135 GO1 Investigators. A phase II, double-blind, randomized, placebo-controlled, dose comparative study of the efficacy, tolerability, and safety of MCC-135 in subjects with chronic heart failure, NYHA class II/III (MCC-135-GO1 study): rationale and design. J Card Fail. 2004 Jun;10(3):193-9. PubMed PMID: 15190528.

9: Satoh N, Kitada Y. Effects of MCC-135 on Ca2+ uptake by sarcoplasmic reticulum and myofilament sensitivity to Ca2+ in isolated ventricular muscles of rats with diabetic cardiomyopathy. Mol Cell Biochem. 2003 Jul;249(1-2):45-51. PubMed PMID: 12956397.

10: Yarbrough WM, Mukherjee R, Escobar GP, Hendrick JW, Sample JA, Dowdy KB, McLean JE, Mingoia JT, Crawford FA Jr, Spinale FG. Modulation of calcium transport improves myocardial contractility and enzyme profiles after prolonged ischemia-reperfusion. Ann Thorac Surg. 2003 Dec;76(6):2054-61; discussion 2061. PubMed PMID: 14667641.

11: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008 May;30(4):313-31. PubMed PMID: 18773127.

12: Bär FW, Tzivoni D, Dirksen MT, Fernández-Ortiz A, Heyndrickx GR, Brachmann J, Reiber JH, Avasthy N, Tatsuno J, Davies M, Hibberd MG, Krucoff MW; CASTEMI Study Group. Results of the first clinical study of adjunctive CAldaret (MCC-135) in patients undergoing primary percutaneous coronary intervention for ST-Elevation Myocardial Infarction: the randomized multicentre CASTEMI study. Eur Heart J. 2006 Nov;27(21):2516-23. Epub 2006 Oct 9. PubMed PMID: 17030521.

13: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007 Jun;29(5):359-73. PubMed PMID: 17805439.

14: Chia S, Senatore F, Raffel OC, Lee H, Wackers FJ, Jang IK. Utility of cardiac biomarkers in predicting infarct size, left ventricular function, and clinical outcome after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. JACC Cardiovasc Interv. 2008 Aug;1(4):415-23. doi: 10.1016/j.jcin.2008.04.010. PubMed PMID: 19463339.

15: Farr MJ, Lang CC, Lamanca JJ, Zile MR, Francis G, Tavazzi L, Gaasch WH, St John Sutton M, Itoh H, Mancini D; MCC-135 GO1 Investigators. Cardiopulmonary exercise variables in diastolic versus systolic heart failure. Am J Cardiol. 2008 Jul 15;102(2):203-6. doi: 10.1016/j.amjcard.2008.03.041. Epub 2008 Jun 12. PubMed PMID: 18602522.

16: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2006 May;28(4):233-77. PubMed PMID: 16801985.

17: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2004 Dec;26(10):801-27. PubMed PMID: 15672123.

18: SoRelle R. Breast-feeding may reduce later blood pressure. Circulation. 2004 Mar 16;109(10):e9017-27. PubMed PMID: 15023898.